Bulk Pharmaceutical API Sources for fostamatinib disodium

Bulk Pharmaceutical API Sources for fostamatinib disodium

Vendor	Vendor Homepage	Vendor Sku	API Url
Finetech Industry Limited		FT-0668866
BOC Sciences		914295-16-2
AKos Consulting & Solutions		AKOS027250823
eNovation Chemicals		D514395
Yuhao Chemical		RT15551
Molport		MolPort-039-139-276
MuseChem		I005450

Fostamatinib Disodium: Bulk API Sourcing Landscape

Last updated: February 19, 2026

This analysis details the current landscape for bulk active pharmaceutical ingredient (API) sourcing of fostamatinib disodium. It identifies key manufacturers, assesses supply chain risks, and outlines regulatory considerations for procurement.

What are the primary API manufacturers for fostamatinib disodium?

Global manufacturing for fostamatinib disodium API is concentrated among a limited number of specialized chemical synthesis companies. These entities possess the technical expertise and Good Manufacturing Practice (GMP) compliant facilities required for pharmaceutical-grade API production. Key players include companies with established expertise in complex organic synthesis and a track record of supplying APIs for regulated markets.

The table below lists known API manufacturers and their general geographic locations. Specific production volumes and capacities are proprietary.

Manufacturer Name	Primary Location	Notes
Patheon Manufacturing Services Inc. (part of Thermo Fisher Scientific)	North America	Known for complex API manufacturing and regulatory support. Specific facility details are not publicly disclosed.
Wuxi AppTec Co., Ltd.	China	A large contract development and manufacturing organization (CDMO) with extensive API synthesis capabilities.
CordenPharma International GmbH	Europe	Offers integrated pharmaceutical manufacturing services, including API production, with multiple sites globally.
Siegfried AG	Europe	A global CDMO specializing in the development and manufacturing of APIs and finished dosage forms.
Dishman Carbogen Amcis Ltd.	India	Provides end-to-end services for API development and manufacturing, with a focus on complex molecules.

These manufacturers operate under strict quality control protocols, including those mandated by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The synthesis of fostamatinib disodium involves multiple chemical steps, requiring precise control over reaction conditions and purification processes to achieve the required purity and impurity profiles.

What are the regulatory requirements for API sourcing?

Procuring bulk fostamatinib disodium API necessitates adherence to stringent global regulatory standards. Key requirements include:

• Good Manufacturing Practices (GMP): Facilities must be GMP-certified by relevant health authorities (e.g., FDA, EMA). This ensures that APIs are consistently produced and controlled according to quality standards. Compliance is verified through regular inspections.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically maintain DMFs (in the U.S.) or ASMFs (in Europe). These confidential documents contain detailed information about the manufacturing process, quality control, and stability of the API. Pharmaceutical companies reference these filings in their drug product applications.
• Impurity Profiling: Comprehensive characterization and control of process-related impurities, degradants, and residual solvents are critical. Limits for impurities are set based on toxicological data and regulatory guidelines, such as those from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
• Stability Testing: Manufacturers must conduct extensive stability studies to determine the shelf life of the API under various storage conditions. This data supports the establishment of appropriate storage and handling recommendations.
• Change Control: Any significant changes to the API manufacturing process, specifications, or manufacturing site must be carefully managed and reported to regulatory authorities and drug product manufacturers.
• Supply Chain Security: Robust measures are required to ensure the integrity and traceability of the API throughout the supply chain, preventing counterfeiting and diversion.

The pharmaceutical company seeking to source fostamatinib disodium API must conduct thorough due diligence on potential suppliers to ensure their compliance with these regulatory mandates. This often involves site audits and a review of quality agreements.

What are the potential supply chain risks associated with fostamatinib disodium API?

The sourcing of fostamatinib disodium API is subject to several supply chain risks. The specialized nature of its synthesis and the limited number of qualified manufacturers contribute to potential vulnerabilities.

• Single/Dual Sourcing: If a drug product relies on a single or very limited number of API suppliers, any disruption at one of these sites can have a significant impact on drug availability. This includes issues such as:

  • Manufacturing Incidents: Equipment failures, quality deviations, or environmental incidents at an API manufacturing facility.
  • Regulatory Actions: FDA or EMA warning letters, import alerts, or facility shutdowns can halt production.
  • Geopolitical Instability: For APIs manufactured in regions prone to political unrest or trade disputes, supply can be jeopardized.
  • Raw Material Shortages: Dependencies on specific raw materials for synthesis can lead to production delays if those materials become scarce.

• Geographic Concentration: A significant portion of global API manufacturing, including for complex molecules like fostamatinib disodium, is concentrated in specific regions, notably China and India. While these regions offer cost advantages and established infrastructure, they also present risks related to:

  • Logistics and Transportation: Delays in shipping, customs issues, or disruptions to international transport routes.
  • Environmental Regulations: Increasing environmental scrutiny in manufacturing hubs can lead to temporary shutdowns or increased compliance costs.
  • Intellectual Property Protection: While improving, concerns about IP protection can influence investment and technology transfer.

• Lead Times and Capacity Constraints: The multi-step synthesis of fostamatinib disodium requires significant lead times. Manufacturers often operate on a campaign basis, meaning production slots are scheduled in advance. Sudden increases in demand or unexpected order volumes can lead to capacity constraints and extended lead times.

• Quality and Compliance Issues: Even with GMP compliance, deviations can occur. A serious quality issue with an API batch can lead to product recalls, regulatory investigations, and the need to re-validate processes with a new supplier, which is a time-consuming and costly undertaking.

To mitigate these risks, pharmaceutical companies often pursue dual-sourcing strategies, qualify multiple suppliers, and maintain safety stocks of critical APIs.

What are the key considerations for quality control of fostamatinib disodium API?

Ensuring the consistent quality of fostamatinib disodium API is paramount for patient safety and drug efficacy. Key quality control considerations include:

• Analytical Method Validation: All analytical methods used to test API purity, potency, and impurity levels must be thoroughly validated according to ICH guidelines. This includes methods for:

  • High-Performance Liquid Chromatography (HPLC) for assay and related substances.
  • Gas Chromatography (GC) for residual solvents.
  • Karl Fischer titration for water content.
  • Spectroscopic methods (e.g., IR, NMR) for identity confirmation.

• Impurity Limits and Specifications: Establishing rigorous specifications for known and unknown impurities is critical. This involves:

  • Process Impurities: Identifying and controlling byproducts of the synthetic route.
  • Degradation Products: Monitoring for impurities that form during storage or handling.
  • Genotoxic Impurities: Specifically assessing and controlling potentially genotoxic impurities to very low levels, as per ICH M7 guidelines.
  • Residual Solvents: Ensuring that residual solvents are within acceptable limits as defined by ICH Q3C.

• Polymorphism: Fostamatinib disodium can exist in different crystalline forms (polymorphs). Controlling the specific polymorphic form is important, as different polymorphs can exhibit variations in solubility, dissolution rate, and bioavailability, potentially impacting drug product performance. Characterization techniques such as X-ray Powder Diffraction (XRPD) and Differential Scanning Calorimetry (DSC) are used.

• Particle Size Distribution (PSD): The particle size of the API can influence its dissolution rate and the manufacturing process of the final drug product (e.g., tablet compression, capsule filling). PSD is typically controlled using milling and micronization techniques, with specifications defined for parameters like D10, D50, and D90.

• Batch-to-Batch Consistency: Manufacturers must demonstrate consistent quality across all production batches. This is achieved through robust process control, in-process testing, and comprehensive release testing of the final API.

Pharmaceutical companies must implement robust incoming quality control testing of API batches from their suppliers and maintain a continuous monitoring program.

What is the patent landscape for fostamatinib disodium and its manufacturing processes?

The patent landscape for fostamatinib disodium is a critical factor in API sourcing and market exclusivity. Patents can cover the compound itself, its salt forms, pharmaceutical compositions, and specific manufacturing processes.

• Composition of Matter Patents: The original patent covering the fostamatinib molecule has expired or is nearing expiration in key markets. For fostamatinib disodium, this would have been filed by the innovator company, likely.([This specific information regarding patent expiry dates would need to be accessed from a dedicated patent database for precise figures and dates.])

• Process Patents: While the compound patent may expire, patents covering novel or improved manufacturing processes can still provide protection for specific synthesis routes. These patents can detail:

  • Specific chemical reactions or catalysts used.
  • Novel purification methods.
  • Methods for controlling specific physical characteristics like particle size or polymorphism.
  • Efficient synthesis routes that reduce cost or improve yield.

Companies developing generic versions of fostamatinib disodium must carefully navigate this patent landscape to avoid infringement. This involves:

• Freedom-to-Operate (FTO) Analysis: Conducting thorough FTO searches to identify any blocking patents for their intended manufacturing process and formulation.
• Non-Infringing Processes: Developing alternative synthesis routes that do not infringe on existing process patents. This is a key strategy for generic API manufacturers.
• Patent Expiries: Monitoring patent expiry dates to identify opportunities for market entry once composition of matter patents lapse.

The expiry of key patents typically opens the market to generic competition, which can lead to increased demand for bulk API from a wider range of manufacturers. However, existing process patents can still limit the available manufacturing routes for generic producers.

Key Takeaways

• Bulk fostamatinib disodium API manufacturing is concentrated among specialized CDMOs with GMP compliance.
• Key regulatory requirements include GMP certification, DMF/ASMF filings, rigorous impurity control, and stability testing.
• Supply chain risks include single/dual sourcing dependency, geographic concentration, logistical challenges, and potential quality deviations.
• Quality control for fostamatinib disodium API focuses on validated analytical methods, strict impurity limits, polymorphic control, and particle size distribution.
• The patent landscape, including composition of matter and process patents, dictates market exclusivity and influences the development of generic manufacturing processes.

Frequently Asked Questions

1. What is the typical lead time for bulk fostamatinib disodium API orders? Lead times can vary significantly depending on the manufacturer's current production schedule, batch size, and complexity of the synthesis. Generally, expect lead times ranging from 3 to 9 months for custom synthesis campaigns, with potential for shorter lead times for established stock or near-term scheduled production runs.

2. Can I use an API manufactured in China or India for U.S. or European drug product approval? Yes, APIs manufactured in China or India can be used for U.S. or European drug product approval, provided the manufacturing facilities are GMP-certified by the respective health authorities (e.g., FDA, EMA) and a compliant DMF or ASMF is filed and accepted. Regular site inspections and robust quality agreements are essential.

3. What is the minimum order quantity for fostamatinib disodium API? Minimum order quantities (MOQs) are determined by the API manufacturer and are typically driven by production batch sizes. For complex APIs like fostamatinib disodium, MOQs can range from tens to hundreds of kilograms, depending on the manufacturer's operational scale.

4. How can I assess the impurity profile of a potential fostamatinib disodium API supplier? A comprehensive assessment involves reviewing the supplier's DMF/ASMF, certificates of analysis (CoAs) for multiple batches, and analytical method validation reports. Site audits are also crucial to observe quality control procedures and discuss impurity control strategies, including those for genotoxic impurities.

5. What are the implications of a patent expiry for fostamatinib disodium API pricing? The expiry of key composition of matter patents generally leads to increased competition from generic manufacturers. This competition typically drives down API pricing due to a larger supplier base and economies of scale achieved by generic producers. However, the presence of strong process patents can limit the number of generic manufacturers and influence price dynamics.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practices (GMP). Retrieved from www.fda.gov

[2] European Medicines Agency. (n.d.). Manufacturing and quality. Retrieved from www.ema.europa.eu

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from www.ich.org

[4] (Information on specific API manufacturers and their capabilities is derived from industry directories and publicly available company information. Specific patent details require access to specialized patent databases.)